Immunosuppressive therapy does not significantly impair the performance of the degranulation assays. Results were pooled from those patients with FHL2, XLP, and secondary HLH for whom information on HLH-2004 or other immunosuppressive treatment (IS) at the time of analysis was available. (A) Analysis of resting NK cells. (B) Analysis of IL-2–activated NK cells.